A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis

Nick Cunniffe; Khue Anh  Vuong; Debbie  Ainslie; David Baker; Judy Beveridge; Sorrel R. B. Bickley; Patrick  Camilleri; Matthew Craner; Denise C Fitzgerald; Alerie Guzman De La Fuente; Gavin Giovannoni; Emma  Gray; Lorraine Hazlehurst; Raj Kapoor; Ranjit  Kaur; David Kozlowski; Brooke  Lumicisi; Don Mahad; Björn  Neumann; Alan Palmer; Luca Peruzzotti-Jametti; Stefano Pluchino; Jennifer Robertson; Alan Rothaul; Lyndsey  Shellard; Kenneth J. Smith; Alastair  Wilkins; Anna C Williams; Alasdair J. Coles

doi:10.1136/jnnp-2020-324286

A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis

Nick Cunniffe, Khue Anh Vuong, Debbie Ainslie, David Baker, Judy Beveridge, Sorrel R. B. Bickley, Patrick Camilleri, Matthew Craner, Denise C Fitzgerald, Alerie Guzman De La Fuente, Gavin Giovannoni, Emma Gray, Lorraine Hazlehurst, Raj Kapoor, Ranjit Kaur, David Kozlowski, Brooke Lumicisi, Don Mahad, Björn Neumann, Alan PalmerLuca Peruzzotti-Jametti, Stefano Pluchino, Jennifer Robertson, Alan Rothaul, Lyndsey Shellard, Kenneth J. Smith, Alastair Wilkins, Anna C Williams, Alasdair J. Coles

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Neurology, Neurosurgery & Psychiatry
DOIs	https://doi.org/10.1136/jnnp-2020-324286
Publication status	Published - 12 Nov 2020

Access to Document

10.1136/jnnp-2020-324286

Anna Williams - AAM - JNNP submission accepted for university open access 28Aug2020
This is the author's peer-reviewed manuscript as accepted for publication.
Accepted author manuscript, 1.14 MBLicence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

https://pubmed.ncbi.nlm.nih.gov/33184094/

Is Fractalkine (CX3CL1) a master regulator of remyelination in MS?
Williams, A.
UK-based charities
1/10/16 → 30/09/19
Project: Research

Cite this

Cunniffe, N., Vuong, K. A., Ainslie, D., Baker, D., Beveridge, J., Bickley, S. R. B., Camilleri, P., Craner, M., Fitzgerald, D. C., De La Fuente, A. G., Giovannoni, G., Gray, E., Hazlehurst, L., Kapoor, R., Kaur, R., Kozlowski, D., Lumicisi, B., Mahad, D., Neumann, B., ... Coles, A. J. (2020). A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2020-324286

@article{1a695de6a85a4b4dbeb7352539cd4b3e,

title = "A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis",

author = "Nick Cunniffe and Vuong, {Khue Anh} and Debbie Ainslie and David Baker and Judy Beveridge and Bickley, {Sorrel R. B.} and Patrick Camilleri and Matthew Craner and Fitzgerald, {Denise C} and {De La Fuente}, {Alerie Guzman} and Gavin Giovannoni and Emma Gray and Lorraine Hazlehurst and Raj Kapoor and Ranjit Kaur and David Kozlowski and Brooke Lumicisi and Don Mahad and Bj{\"o}rn Neumann and Alan Palmer and Luca Peruzzotti-Jametti and Stefano Pluchino and Jennifer Robertson and Alan Rothaul and Lyndsey Shellard and Smith, {Kenneth J.} and Alastair Wilkins and Williams, {Anna C} and Coles, {Alasdair J.}",

year = "2020",

month = nov,

day = "12",

doi = "10.1136/jnnp-2020-324286",

language = "English",

journal = "Journal of Neurology, Neurosurgery & Psychiatry",

issn = "0022-3050",

publisher = "BMJ Publishing Group",

}

Cunniffe, N, Vuong, KA, Ainslie, D, Baker, D, Beveridge, J, Bickley, SRB, Camilleri, P, Craner, M, Fitzgerald, DC, De La Fuente, AG, Giovannoni, G, Gray, E, Hazlehurst, L, Kapoor, R, Kaur, R, Kozlowski, D, Lumicisi, B, Mahad, D, Neumann, B, Palmer, A, Peruzzotti-Jametti, L, Pluchino, S, Robertson, J, Rothaul, A, Shellard, L, Smith, KJ, Wilkins, A, Williams, AC & Coles, AJ 2020, 'A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis', Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2020-324286

TY - JOUR

T1 - A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis

AU - Cunniffe, Nick

AU - Vuong, Khue Anh

AU - Ainslie, Debbie

AU - Baker, David

AU - Beveridge, Judy

AU - Bickley, Sorrel R. B.

AU - Camilleri, Patrick

AU - Craner, Matthew

AU - Fitzgerald, Denise C

AU - De La Fuente, Alerie Guzman

AU - Giovannoni, Gavin

AU - Gray, Emma

AU - Hazlehurst, Lorraine

AU - Kapoor, Raj

AU - Kaur, Ranjit

AU - Kozlowski, David

AU - Lumicisi, Brooke

AU - Mahad, Don

AU - Neumann, Björn

AU - Palmer, Alan

AU - Peruzzotti-Jametti, Luca

AU - Pluchino, Stefano

AU - Robertson, Jennifer

AU - Rothaul, Alan

AU - Shellard, Lyndsey

AU - Smith, Kenneth J.

AU - Wilkins, Alastair

AU - Williams, Anna C

AU - Coles, Alasdair J.

PY - 2020/11/12

Y1 - 2020/11/12

U2 - 10.1136/jnnp-2020-324286

DO - 10.1136/jnnp-2020-324286

M3 - Article

SN - 0022-3050

JO - Journal of Neurology, Neurosurgery & Psychiatry

JF - Journal of Neurology, Neurosurgery & Psychiatry

ER -

A systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis

Access to Document

Projects

Is Fractalkine (CX3CL1) a master regulator of remyelination in MS?

Cite this